CANCER:

Non Small Cell Lung Cancer

Related cancers:

‹

Lung Adenocarcinoma (399)

Lung Non-Squamous Non-Small Cell Cancer (80)

Lung Non-Small Cell Squamous Cancer (79)

Lung Adenocarcinoma (399)

Lung Non-Squamous Non-Small Cell Cancer (80)

Lung Non-Small Cell Squamous Cancer (79)

›

PTPRT mutation PTPRT mutation	Non Small Cell Lung Cancer NSCLC	PTPRT mutation PTPRT mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Cancer Med - 2 days	Immunotherapy Sensitive: C3 – Early Trials Cancer Med - 2 days
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	pembrolizumab + lenvatinib Sensitive: B - Late Trials ESMO-IO 2021 - 4 days	pembrolizumab + lenvatinib Sensitive: B - Late Trials ESMO-IO 2021 - 4 days
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: C3 – Early Trials ESMO-IO 2021 - 4 days	tislelizumab Sensitive: C3 – Early Trials ESMO-IO 2021 - 4 days
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: C3 – Early Trials ESMO-IO 2021 - 4 days	tislelizumab Sensitive: C3 – Early Trials ESMO-IO 2021 - 4 days
ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	crizotinib + alectinib Sensitive: C3 – Early Trials Thorac Cancer - 5 days	crizotinib + alectinib Sensitive: C3 – Early Trials Thorac Cancer - 5 days
HER-2 exon 20 mutation HER-2 exon 20 mutation	Non Small Cell Lung Cancer NSCLC	HER-2 exon 20 mutation HER-2 exon 20 mutation	Non Small Cell Lung Cancer NSCLC	HM 78136B Sensitive: B - Late Trials J Clin Oncol - 1 week	HM 78136B Sensitive: B - Late Trials J Clin Oncol - 1 week
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval Sci Rep - 6 days	osimertinib Sensitive: A1 - Approval Sci Rep - 6 days
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval Invest New Drugs - 2 weeks	osimertinib Sensitive: A1 - Approval Invest New Drugs - 2 weeks
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	tepotinib Sensitive: A1 - Approval Clin Cancer Res - 2 weeks	tepotinib Sensitive: A1 - Approval Clin Cancer Res - 2 weeks
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: A1 - Approval Roche Press Release - 2 weeks	pralsetinib Sensitive: A1 - Approval Roche Press Release - 2 weeks
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	aumolertinib Sensitive: A1 - Approval J Thorac Oncol - 2 weeks	aumolertinib Sensitive: A1 - Approval J Thorac Oncol - 2 weeks
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	MT-6402 Sensitive: B - Late Trials Molecular Templates Press Release - 2 weeks	MT-6402 Sensitive: B - Late Trials Molecular Templates Press Release - 2 weeks
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials Ann Oncol - 2 weeks	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials Ann Oncol - 2 weeks
PD-L1 underexpression PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 underexpression PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	nivolumab + ipilimumab Sensitive: C1 - Off-label Thorac Cancer - 2 weeks	nivolumab + ipilimumab Sensitive: C1 - Off-label Thorac Cancer - 2 weeks
PD-L1 underexpression PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 underexpression PD-L1 underexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: C3 – Early Trials Thorac Cancer - 2 weeks	pembrolizumab Sensitive: C3 – Early Trials Thorac Cancer - 2 weeks
HER-2 D769Y HER-2 D769Y	Lung Adenocarcinoma LUAD	HER-2 D769Y HER-2 D769Y	Lung Adenocarcinoma LUAD	afatinib + anlotinib Sensitive: C4 – Case Studies World J Surg Oncol - 2 weeks	afatinib + anlotinib Sensitive: C4 – Case Studies World J Surg Oncol - 2 weeks
EGFR E709_T710delinsD EGFR E709_T710delinsD	Non Small Cell Lung Cancer NSCLC	EGFR E709_T710delinsD EGFR E709_T710delinsD	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: C4 – Case Studies J Med Case Rep - 2 weeks	afatinib Sensitive: C4 – Case Studies J Med Case Rep - 2 weeks
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	sotorasib Sensitive: A1 - Approval Amgen Press Release - 3 weeks	sotorasib Sensitive: A1 - Approval Amgen Press Release - 3 weeks
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials BMC Cancer - 3 weeks	PD-L1 inhibitor Sensitive: C3 – Early Trials BMC Cancer - 3 weeks
MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	MET amplification MET amplification	Non Small Cell Lung Cancer NSCLC	c-MET inhibitor Sensitive: C3 – Early Trials Exp Hematol Oncol - 3 weeks	c-MET inhibitor Sensitive: C3 – Early Trials Exp Hematol Oncol - 3 weeks
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials BMC Cancer - 3 weeks	PD1 inhibitor Sensitive: C3 – Early Trials BMC Cancer - 3 weeks
EGFR L747_T751delinsP EGFR L747_T751delinsP	Non Small Cell Lung Cancer NSCLC	EGFR L747_T751delinsP EGFR L747_T751delinsP	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: C3 – Early Trials BMC Cancer - 3 weeks	EGFR inhibitor Sensitive: C3 – Early Trials BMC Cancer - 3 weeks
PD-L1 expression + EGFR mutation PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 expression + EGFR mutation PD-L1 expression + EGFR mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: C4 – Case Studies J Oncol Pharm Pract - 2 weeks	pembrolizumab Sensitive: C4 – Case Studies J Oncol Pharm Pract - 2 weeks
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A2 - Guideline SITC 2021 - 3 weeks	pembrolizumab Sensitive: A2 - Guideline SITC 2021 - 3 weeks
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: B - Late Trials SITC 2021 - 3 weeks	Immunotherapy Sensitive: B - Late Trials SITC 2021 - 3 weeks
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	BGB324 Sensitive: B - Late Trials BerGenBio Press Release - 3 weeks	BGB324 Sensitive: B - Late Trials BerGenBio Press Release - 3 weeks
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab + BGB324 Sensitive: B - Late Trials SITC 2021 - 3 weeks	pembrolizumab + BGB324 Sensitive: B - Late Trials SITC 2021 - 3 weeks
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval SITC 2021 - 3 weeks	atezolizumab Sensitive: A1 - Approval SITC 2021 - 3 weeks
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval SITC 2021 - 3 weeks	pembrolizumab Sensitive: A1 - Approval SITC 2021 - 3 weeks
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: C1 - Off-label SITC 2021 - 3 weeks	pembrolizumab Sensitive: C1 - Off-label SITC 2021 - 3 weeks
HER-2 amplification HER-2 amplification	Non Small Cell Lung Cancer NSCLC	HER-2 amplification HER-2 amplification	Non Small Cell Lung Cancer NSCLC	pyrotinib Sensitive: C2 – Inclusion Criteria Clin Cancer Res - 3 weeks	pyrotinib Sensitive: C2 – Inclusion Criteria Clin Cancer Res - 3 weeks
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials SITC 2021 - 3 weeks	Immunotherapy Sensitive: C3 – Early Trials SITC 2021 - 3 weeks
TNFRSF14 overexpression TNFRSF14 overexpression	Non Small Cell Lung Cancer NSCLC	TNFRSF14 overexpression TNFRSF14 overexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials SITC 2021 - 3 weeks	Immunotherapy Sensitive: C3 – Early Trials SITC 2021 - 3 weeks
TNFRSF18 overexpression TNFRSF18 overexpression	Non Small Cell Lung Cancer NSCLC	TNFRSF18 overexpression TNFRSF18 overexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials SITC 2021 - 3 weeks	Immunotherapy Sensitive: C3 – Early Trials SITC 2021 - 3 weeks
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	pembrolizumab + MK-1308 Sensitive: C3 – Early Trials SITC 2021 - 3 weeks	pembrolizumab + MK-1308 Sensitive: C3 – Early Trials SITC 2021 - 3 weeks
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials SITC 2021 - 3 weeks	pembrolizumab + MK-4280 Sensitive: C3 – Early Trials SITC 2021 - 3 weeks
EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	EGFR expression EGFR expression	Non Small Cell Lung Cancer NSCLC	cetuximab + CYNK-101 Sensitive: D – Preclinical SITC 2021 - 3 weeks	cetuximab + CYNK-101 Sensitive: D – Preclinical SITC 2021 - 3 weeks
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	ramucirumab Sensitive: A1 - Approval	ramucirumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A1 - Approval	lorlatinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval	osimertinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A1 - Approval	alectinib Sensitive: A1 - Approval
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval	brigatinib Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval	brigatinib Sensitive: A1 - Approval
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A1 - Approval	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: A1 - Approval	lazertinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	capmatinib Sensitive: A1 - Approval	capmatinib Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval	cemiplimab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	cisplatin + pemetrexed Sensitive: A1 - Approval	cisplatin + pemetrexed Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval	cisplatin Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval	crizotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval	crizotinib Sensitive: A1 - Approval
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	selpercatinib Sensitive: A1 - Approval	selpercatinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	mobocertinib Sensitive: A1 - Approval	mobocertinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: A1 - Approval	tislelizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	DP Sensitive: A1 - Approval	DP Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	savolitinib Sensitive: A1 - Approval	savolitinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: A1 - Approval	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pemetrexed Sensitive: A1 - Approval	pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval	cisplatin + pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	nintedanib Sensitive: A1 - Approval	nintedanib Sensitive: A1 - Approval
EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval	necitumumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval	trametinib + dabrafenib Sensitive: A1 - Approval
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw Sensitive: A1 - Approval	amivantamab-vmjw Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	docetaxel Sensitive: A1 - Approval	docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A1 - Approval	ceritinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + erlotinib Sensitive: A1 - Approval	bevacizumab + erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: A1 - Approval	sintilimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval	erlotinib + ramucirumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval	erlotinib + ramucirumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Non Small Cell Lung Cancer NSCLC	BRAF V600 BRAF V600	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval	trametinib + dabrafenib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	tislelizumab Sensitive: A1 - Approval	tislelizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval	cemiplimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	sintilimab Sensitive: A1 - Approval	sintilimab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
EGFR mutation + ALK negative + TMB-H EGFR mutation + ALK negative + TMB-H	Non Small Cell Lung Cancer NSCLC	EGFR mutation + ALK negative + TMB-H EGFR mutation + ALK negative + TMB-H	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A2 - Guideline	ceritinib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A2 - Guideline	alectinib Sensitive: A2 - Guideline
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A2 - Guideline	lorlatinib Sensitive: A2 - Guideline
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A2 - Guideline	osimertinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Sensitive: A2 - Guideline	ALK inhibitor Sensitive: A2 - Guideline
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A2 - Guideline	erlotinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	vemurafenib Sensitive: A2 - Guideline	vemurafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A2 - Guideline	pemetrexed Sensitive: A2 - Guideline

Non Small Cell Lung Cancer

Associations(2270)

Associations
(2270)